| Literature DB >> 26355275 |
I Van't Hooft1,2, A Lindahl Norberg1,3, A Björklund4, M Lönnerblad2,5, B Strömberg4,6.
Abstract
AIM: The aim of this study was to coordinate the structured psychosocial, neurocognitive and educational follow-up of children treated for brain tumours with the medical protocol and apply the model in two Swedish healthcare regions.Entities:
Keywords: Multiprofessional care; Neurocognitive performance; Paediatric brain tumours; Poor emotional status; Special needs
Mesh:
Year: 2015 PMID: 26355275 PMCID: PMC5063152 DOI: 10.1111/apa.13207
Source DB: PubMed Journal: Acta Paediatr ISSN: 0803-5253 Impact factor: 2.299
Figure 1Attrition.
Characteristics of patients diagnosed with brain tumours in the Stockholm (St) and Uppsala–Örebro (U–Ö) healthcare regions during the project period
| Patient characteristics | All diagnosed brain tumours (n = 61:38 in Stockholm and 23 in Uppsala–Örebro) | Provided informed consent (n = 43:26 in Stockholm and 17 in Uppsala–Örebro) | Children who died during the project period (n = 11:7 in Stockholm and 4 in Uppsala–Örebro) |
|---|---|---|---|
| Sex (male/female) | 42/19 | 28/16 | 7/4 |
| Median age at diagnosis (range) | 6.8 (0.2–17.1) | 5.3 (0.2–17.1) | 8.0 (0.3–17.1) |
| Type of tumour | |||
| Astrocytoma | 23 | 16 | 4 |
| Medulloblastoma | 8 | 5 | |
| Brain stem glioma | 8 | 6 | 4 |
| Optic glioma | 5 | 5 | 1 |
| Ependymoma | 4 | 3 | 1 |
| Plexus papilloma/carcinoma | 3 | 3 | |
| Craniopharyngioma | 3 | 2 | |
| Other tumours | 7 | 3 | 1 |
| Type of treatment | |||
| Surgery only | 25 | 13 | 1 |
| Surgery + radiotherapy | 5 | 6 | |
| Surgery + chemotherapy | 5 | 5 | 1 |
| Surgery + radiotherapy + chemotherapy | 14 | 8 | 5 |
| Chemotherapy only | 7 | 4 | |
| Radiotherapy + chemotherapy | 4 | 4 | 4 |
| Expectant | 1 | 1 | |
Two children with tuberous sclerosis and giant‐cell astrocytoma.
Not biopsied.
Dysembryoplastic epithelial tumour (DNET) 2; ganglioglioma 1; oligodendroglioma 1; neurocytoma 1; atypical teratoid rhabdoid tumour (ATRT) 1; supratentorial tumour of unknown type 1.
Figure 2Overview of the follow‐up programme.